drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis药敏在利什曼原虫分离株miltefosine治疗内脏利什曼病和post黑热病病例皮肤利什曼病.pdfVIP

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis 1. 1. 1 2 Vasundhra Bhandari , Arpita Kulshrestha , Deepak Kumar Deep , Olivia Stark , Vijay 3 4 3 2 5 Kumar Prajapati , V. Ramesh , Shyam Sundar , Gabriele Schonian , Jean Claude Dujardin , Poonam Salotra1* 1 National Institute of Pathology, Indian Council of Medical Research, Safdarjung Hospital Campus, New Delhi, India, 2 Institute of Microbiology and Hygiene, Charite University Medicine Berlin, Berlin, Germany, 3 Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, 4 Department of Dermatology, Safdarjung Hospital, New Delhi, India, 5 Unit of Molecular Parasitology, Department of Parasitology, Institute of Tropical Medicine, Antwerp, Belgium Abstract Background: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the VL elimination program. Methodology and Principal Findings: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L. donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL susceptibility of post-treatment isolates from cured VL cases (n = 13, mean IC50 6SD = 2.43 61.44 mM), was comparable (p.0.05) whereas that from relapses (n = 3, mean IC5